EUCTR2021-005329-26-NO进行中（未招募）1 期
A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Symptomatic Nonobstructive Hypertrophic Cardiomyopathy - Mavacamten in nonobstructive HCM
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 420
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Participants must be at least 18 years old or local age of majority at the time of signing the informed consent
- •2. Female participants must adhere to highly effective contraceptive methods or have documented proof that they are not of childbearing potential
- •3. No additional contraceptive measures are required to be used for male participants
- •4. Diagnosis of HCM consistent with current American College of Cardiology Foundation/American Heart Association and European Society of Cardiology guidelines.
- •5. Peak LVOT pressure gradient < 30 mmHg at rest and < 50 mmHg with provocation (Valsalva maneuver and stress echocardiography)
- •6. CPET: Documented oxygen saturation at rest >90% at Screening. Able to perform an upright cardiopulmonary stress test (CPET) and has a respiratory exchange ratio (RER) = 1.0 at Screening per central reading. If the RER is between 0.91 and 1.0, the participant may be enrolled if the central CPET laboratory determines that peak exercise has been achieved. Participants with subpeak performance may not be enrolled as described in the CPET Laboratory Manual.
- •7. New York Heart Association (NYHA) Class II or III
- •8. NT-proBNP=200 pg/mL or BNP=70 pg/mL
- •9. LVEF =60 % as determined by the echocardiography central laboratory
- •10. KCCQ-23 CSS Score = 85 at screening
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 400
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •Medical Conditions
- •- Known infiltrative or storage disorder causing cardiac hypertrophy that mimics nHCM such as Fabry disease, amyloidosis, or Noonan syndrome with LV hypertrophy
- •Note: Investigators should not screen participants who have comprehensive Echo features suggestive of amyloidosis, including abnormal global longitudinal strain in the setting of an appropriate clinical picture which could include low voltage on ECG and severely elevated NT-proBNP or BNP
- •- History of unexplained syncope within 6 months prior to screening
- •- History of sustained ventricular tachyarrhythmia (> 30 seconds) within 6 months prior to Screening
- •- Paroxysmal or persistent (non-permanent) AF detected at the time of screening. Permanent AF is allowed if the participant is anticoagulated and the investigator considers the heart rate adequately controlled
- •- CV diseases or treatments that in the opinion of the investigator increase the unpredictability of or change the participants’ clinical course.
- •- Acute heart failure from 4 weeks prior to screening up to randomization
- •- Coronary artery disease requiring intervention, including myocardial infarction (increase in cardiac enzymes in combination with symptoms of ischemia or new ischemic ECG changes), coronary artery bypass graft surgery, or other major CV surgery, stroke, or transient ischemic attack in the past 90 days
- •- Women who are breastfeeding or pregnant.
- •Prior/Concomitant Therapy
- •- Any adjustments of beta-blockers, verapamil, or diltiazem within 2 weeks prior to Screening and up to the day of randomization
- •- Concomitant use of strong inhibitors of cytochrome P450 (CYP) 2C19
- •Note: Use should be discontinued for a minimum of 5 elimination half-lives prior to first dose of study intervention.
- •Other Exclusion Criteria
- •- Any other serious condition that in the opinion of the investigator could prevent participation in the study and follow-up, including active infection with COVID-19 from 4 weeks prior to screening up to randomization
- •- Completed a study with an investigational device < 30 days prior to screening or an investigational drug 5 half-lives prior to screening
- •- Participants who have completed a study with mavacamten or aficamten
- •-Enrolled in another study and receiving any investigational treatment (device or drug) other than the study intervention given in this study.
研究者
相似试验
招募中
1 期
A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with CardiomyopathyEUCTR2021-005329-26-NLMyokardia, Inc.420
招募中
3 期
Mavacamten in non-obstructive HCMsymptomatic non-obstructive hypertrophic cardiomyopathy (nHCM)JPRN-jRCT2051220175Aronson Ron34
进行中（未招募）
1 期
A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with CardiomyopathySymptomatic Nonobstructive Hypertrophic CardiomyopathyMedDRA version: 20.0Level: PTClassification code 10049813Term: Non-obstructive cardiomyopathySystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 20.0Level: PTClassification code 10020871Term: Hypertrophic cardiomyopathySystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2021-005329-26-DEMyokardia, Inc.420
招募中
3 期
A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Symptomatic Non-obstructive Hypertrophic CardiomyopathyNL-OMON56426Myokardia, Inc.31
进行中（未招募）
1 期
A Study of Mavacamten in Adolescent Participants with Symptomatic Obstructive Hypertrophic CardiomyopathySymptomatic Obstructive Hypertrophic CardiomyopathyMedDRA version: 20.0Level: LLTClassification code: 10020876Term: Hypertrophic obstructive cardiomyopathy Class: 10010331CTIS2023-505650-17-00Bristol-Myers Squibb Services Unlimited Company40